This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Well Characterized Biologics & Biological Assays
Well Characterized Biologics & Biological Assays is now part of BioProcess International
September 23-26, 2024Hynes Convention Center in Boston, USA

Joseph Hazelton
Chief Business Officer at Dyadic


Joseph Hazelton is Dyadic’s Chief Business Officer, I have added his bio below if needed. We will get the presentation to you asap!

The newest member of the executive leadership team, Joe Hazelton, was appointed Chief Business Officer in November 2021. Mr. Hazelton is responsible for global commercialization of Dyadic’s new and existing business initiatives, including corporate strategy, business and corporate development and licensing. His appointment reinforces Dyadic’s commitment to maximize the integration of the C1 platform across life sciences and pharma in addition to opportunities in other industries.

A recognized industry veteran, Joe brings over 20 years of pharmaceutical experience in key growth areas of product and business development, licensing, and commercialization. Mr. Hazelton began his career in 1998 with Novartis Pharmaceuticals Corporation, where he held leadership positions within the core functions of sales, marketing, market access, pricing, contracting, and strategic alliances for various retail and specialty pharmaceuticals across a broad spectrum of therapeutic areas and several blockbuster products. Prior to joining Dyadic, he served as Chief Operating Officer and Chief Commercial Officer for Charleston Laboratories Inc., responsible for the strategic management of Charleston’s product and portfolio management, alliance management, regulatory oversight, and global commercialization activities.

Agenda Sessions

  • C1 Gene Expression Platform: Rapid, High Yield and Lower Cost Way to Develop and Manufacture Biologics